Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Medication Systems Clear all
Completed Phase 1 Interventional

A Study of 1592U89 and Ethanol When Given Together to HIV-Infected Patients

NCT00002198
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

NCT01026233
View directory record Official record
Conditions
Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
Interventions
brentuximab vedotin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Birmingham, Alabama • Duarte, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 1Phase 2 Interventional

Transplant and Addiction Project (TAP) - 1

NCT00249652
View directory record Official record
Conditions
End Stage Liver Disease, End Stage Renal Disease, Substance-Related Disorders
Interventions
TAP, TAU
Behavioral · Other
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
3
States / cities
New York, New York • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Not applicable Interventional

Effectiveness of Creatine in Preventing Muscle Aching From Cholesterol-Lowering Statin Drugs

NCT00797407
View directory record Official record
Conditions
Hypercholesterolemia, Aches, Cramps, Weakness
Interventions
Creatine
Dietary Supplement
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Wooster, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 24, 2008 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Not applicable Interventional Results available

Medication Adherence With Polyglot Meducation

NCT01744392
View directory record Official record
Conditions
Hypertension, Diabetes, Hypercholesterolemia
Interventions
education intervention
Behavioral
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children

NCT00000893
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 16 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
25
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 2 Interventional

The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 Weeks

NCT00001063
View directory record Official record
Conditions
HIV Infections
Interventions
Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
31
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 10, 2026, 4:14 PM EDT
Recruiting Phase 1 Interventional

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

NCT06041516
View directory record Official record
Conditions
Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine, Carcinoma, Adrenocortical, Carcinoma, Adrenal Cortical
Interventions
ADCT-701
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Early Phase 1 Interventional

Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations

NCT02646319
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma, Endometrial Carcinoma, Malignant Uterine Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Malignant Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Solid Neoplasm, Stage III Bladder Cancer, Stage III Prostate Cancer, Stage III Renal Cell Cancer, Stage IIIA Breast Cancer, Stage IIIA Cervical Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Breast Cancer, Stage IIIB Cervical Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Breast Cancer, Stage IIIC Ovarian Cancer, Stage IV Breast Cancer, Stage IV Ovarian Cancer, Stage IV Prostate Cancer, Stage IV Renal Cell Cancer, Stage IVA Bladder Cancer, Stage IVA Cervical Cancer, Stage IVB Bladder Cancer, Stage IVB Cervical Cancer
Interventions
Laboratory Biomarker Analysis, Nanoparticle Albumin-Bound Rapamycin, Quality-of-Life Assessment
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Sep 10, 2026, 4:14 PM EDT
Withdrawn Phase 3 Interventional

A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus

NCT02106364
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Peglispro, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Zephyrhills, Florida • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2016 · Synced Sep 10, 2026, 4:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

NCT07145255
View directory record Official record
Conditions
Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell), Pancreas Cancer, Duct Cell Adenocarcinoma
Interventions
ADC
Drug
Lead sponsor
MBrace Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
San Francisco, California • Grand Rapids, Michigan • East Brunswick, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Terminated Not applicable Interventional

Betaquik as an Adjunct to Dietary Management of Epilepsy in Adults on the Modified Atkins Diet

NCT03790436
View directory record Official record
Conditions
Epilepsy, Epilepsy Intractable, Seizures, Seizure Disorder, Ketogenic Dieting, Ketosis
Interventions
Betaquik
Dietary Supplement
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 30, 2022 · Synced Sep 10, 2026, 4:14 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:

NCT06322238
View directory record Official record
Conditions
Pharmacogenomic Drug Interaction, Side Effect of Drug, Ineffective Drug Action, Drug Metabolism, Poor, CYP2D6-Related, Drug Metabolism, Poor, CYP2C19-Related
Interventions
PGx panel test
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients

NCT00507442
View directory record Official record
Conditions
Multiple Myeloma
Interventions
VELCADE (bortezomib), dexamethasone, cyclophosphamide, Revlimid (lenalidomide)
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Denver, Colorado • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

NCT03373383
View directory record Official record
Conditions
Drug-resistant Epilepsy, Focal-Onset Seizures
Interventions
Padsevonil, Placebo
Drug · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Chandler, Arizona • Little Rock, Arkansas • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Acute and Residual Effects of Caffeinated Beer

NCT00515294
View directory record Official record
Conditions
Neurobehavioral Manifestations, Drug Related Sleep Disturbance, Alcohol Intoxication
Interventions
Caffeinated Alcoholic Beer, Non-Caffeinated Alcoholic Beer, Caffeinated Non-Alcoholic Beer, Non-Caffeinated, Non-Alcoholic Beer
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
21 Years to 30 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Sep 10, 2026, 4:14 PM EDT
Not yet recruiting Not applicable Interventional

EASEE® System Pivotal Study for the United States of America

NCT07301346
View directory record Official record
Conditions
Drug-Resistant Focal Epilepsy
Interventions
Implantable minimaly invasive brain stimulator
Device
Lead sponsor
Precisis US, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Active, not recruiting Not applicable Interventional

Community-based Education, Navigation, and Support Intervention for Military Veterans

NCT05343169
View directory record Official record
Conditions
Overdose, Opioid Use Disorder, HIV Infections
Interventions
Overdose Education and Naloxone Distribution, Advanced Education in Safer Substance Use, Treatment, and Self-Care, Social Service and Health Navigation, Peer Social Support
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)

NCT03165227
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
BI 685509, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
22
States / cities
Huntsville, Alabama • La Mesa, California • Los Gatos, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Not applicable Interventional

Intervention Targeting Medication Adherence and Methamphetamine Use in HIV Positive Men (ACE)

NCT01122186
View directory record Official record
Conditions
HIV Medication Adherence, Methamphetamine Use, Sexual Risk, Poly-substance Use, HIV Infections
Interventions
Motivational Interviewing + Cognitive Behavioral Skills Training, Education Attention Control
Behavioral
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
18 Years and older · Male only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Not applicable Interventional

A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis

NCT00002305
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Flucytosine, Fluconazole, Amphotericin B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 4 Interventional

A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV

NCT00082394
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
Trizivir, atazanavir, Combivir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
43
States / cities
Bakersfield, California • Los Angeles, California • Oakland, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

NCT01572727
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, BKM120 matching placebo, BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
21
States / cities
Chandler, Arizona • Phoenix, Arizona • Fayetteville, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Early Phase 1 Interventional Results available

The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome

NCT01102270
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Eszopiclone, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 10, 2026, 4:14 PM EDT